SEARCH

SEARCH BY CITATION

References

  • Alves da Costa C. and Checler F. (2011) Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell. Signal. 23, 963968.
  • Barten D. M. and Albright C. F. (2008) Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol. 37, 171186.
  • Beckerle M. C. (1997) Zyxin: zinc fingers at sites of cell adhesion. BioEssays 19, 949957.
  • Bitan G., Kirkitadze M. D., Lomakin A., Vollers S. S., Benedek G. B. and Teplow D. B. (2003) Amyloid beta -protein (Abeta) assembly: abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl Acad. Sci. USA 100, 330335.
  • Copani A., Caraci F., Hoozemans J. J., Calafiore M., Sortino M. A. and Nicoletti F. (2007) The nature of the cell cycle in neurons: focus on a “non-canonical” pathway of DNA replication causally related to death. Biochim. Biophys. Acta 1772, 409412.
  • Copani A., Guccione S., Giurato L., Caraci F., Calafiore M., Sortino M. A. and Nicoletti F. (2008) The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development. Curr. Med. Chem. 15, 24202432.
  • Crone J., Glas C., Schultheiss K., Moehlenbrink J., Krieghoff-Henning E. and Hofmann T. G. (2011) Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis. Cancer Res. 71, 23502359.
  • Degenhardt Y. Y. and Silverstein S. (2001) Interaction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocation. J. Virol. 75, 1179111802.
  • Fujita Y., Yamaguchi A., Hata K., Endo M., Yamaguchi N. and Yamashita T. (2009) Zyxin is a novel interacting partner for SIRT1. BMC Cell Biol. 10, 6.
  • Hervy M., Hoffman L. M., Jensen C. C., Smith M. and Beckerle M. C. (2010) The LIM protein zyxin binds CARP-1 and promotes apoptosis. Genes Cancer 1, 506515.
  • Joerger A. C. and Fersht A. R. (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 22262242.
  • Jope R. S., Yuskaitis C. J. and Beurel E. (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32, 577595.
  • Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S. and Malinow R. (2003) APP processing and synaptic function. Neuron 37, 925937.
  • Kato T., Muraski J., Chen Y., Tsujita Y., Wall J., Glembotski C. C., Schaefer E., Beckerle M. and Sussman M. A. (2005) Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J. Clin. Invest. 115, 27162730.
  • Knauer M. F., Soreghan B., Burdick D., Kosmoski J. and Glabe C. G. (1992) Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc. Natl Acad. Sci. USA 89, 74377441.
  • Lanni C., Mazzucchelli M., Porrello E., Govoni S. and Racchi M. (2004) Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. Eur. J. Biochem. 271, 30683075.
  • Lanni C., Uberti D., Racchi M., Govoni S. and Memo M. (2007) Unfolded p53: a potential biomarker for Alzheimer's disease. J. Alzheimers Dis. 12, 9399.
  • Lanni C., Racchi M., Mazzini G. et al. (2008) Conformationally altered p53: a novel Alzheimer's disease marker?. Mol. Psychiatry 13, 641647.
  • Lanni C., Nardinocchi L., Puca R., Stanga S., Uberti D., Memo M., Govoni S., D'Orazi G. and Racchi M. (2010) Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS ONE 5, e10171.
  • Lanni C., Racchi M., Memo M., Govoni S. and Uberti D. (2012) p53 at the crossroads between cancer and neurodegeneration. Free Radic. Biol. Med. 52, 17271733.
  • Li T., Wen H., Brayton C. et al. (2007) Moderate reduction of γ-secretase attenuates amyloid burden and limits mechanism-based liabilities. J. Neurosci. 27, 1084910859.
  • Lu K. P. and Zhou X. Z. (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signaling and disease. Nat. Rev. Mol. Cell Biol. 8, 904916.
  • Mayeux R., Tang M. X., Jacobs D. M., Manly J., Bell K., Merchant C., Small S. A., Stern Y., Wisniewski H. M. and Mehta P. D. (1999) Plasma amyloid beta-peptide 1–42 and incipient Alzheimer's disease. Ann. Neurol. 46, 412416.
  • Méplan C., Richard M. J. and Hainaut P. (2000) Redox signalling and transition metals in the control of the p53 pathway. Biochem. Pharmacol. 59, 2533.
  • Pangalos M. N., Jacobsen S. J. and Reinhart P. H. (2005) Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem. Soc. Trans. 33, 553558.
  • Puca R., Nardinocchi L., Gal H. et al. (2008) Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. 68, 37073714.
  • Puca R., Nardinocchi L., Bossi G., Sacchi A., Rechavi G., Givol D. and D'Orazi G. (2009) Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp. Cell Res. 315, 6775.
  • Sadot E., Geiger B., Oren M. and Ben-Ze'ev A. (2001) Down-regulation of beta-catenin by activated p53. Mol. Cell. Biol. 21, 67686781.
  • Terai K., Iwai A., Kawabata S., Tasaki Y., Watanabe T., Miyata K. and Yamaguchi T. (2001) Amyloid-deposits in transgenic mice expressing human β amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 104, 299310.
  • Uberti D., Carsana T., Bernardi E., Rodella L., Grigolato P., Lanni C., Racchi M., Govoni S. and Memo M. (2002) Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J. Cell Sci. 115, 31313138.
  • Uberti D., Lanni C., Carsana T., Francisconi S., Missale C., Racchi M., Govoni S. and Memo M. (2006) Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol. Aging 27, 11931201.
  • Uberti D., Cenini G., Olivari L. et al. (2007) Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J. Neurochem. 103, 322333.
  • Verdile G., Fuller S., Atwood C. S., Laws S. M., Gandy S. E. and Martins R. N. (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol. Res. 50, 397409.
  • Vousden K. H. and Prives C. (2005) P53 and prognosis: new insights and further complexity. Cell 120, 710.
  • Walsh D. M. and Selkoe D. J. (2007) Aβ Oligomers-a decade of discovery. J. Neurochem. 101, 11721184.
  • Wang Y. and Gilmore T. D. (2001) LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim. Biophys. Acta 1538, 260272.
  • Wang Y. and Gilmore T. D. (2003) Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim. Biophys. Acta 1593, 115120.
  • Wang S., Konorev E. A., Kotamraju S., Joseph J., Kalivendi S. and Kalyanaraman B. (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 279, 2553525543.
  • Yang Y., Geldmacher D. S. and Herrup K. (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J. Neurosci. 21, 26612668.
  • Zhou X. and Jia J. (2010) P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neurosci. Lett. 468, 320325.